Patents by Inventor Agnes Nowakowski

Agnes Nowakowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150175701
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 25, 2015
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Patent number: 8906369
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 9, 2014
    Assignee: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Publication number: 20130232589
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 5, 2013
    Applicant: diaDexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Patent number: 8444971
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: May 21, 2013
    Assignee: Diadexus, Inc.
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
  • Publication number: 20100136009
    Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovrl 10 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovrl 10-expressing cancer cells and alleviating or treating an Ovrl 10-expressing cancer in a mammal. The anti-Ovrl 10 antibodies modulate Ovrl 10 function or internalize upon binding to Ovrl 10 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovrl 10 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovrl 10 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
    Type: Application
    Filed: November 27, 2007
    Publication date: June 3, 2010
    Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski